Interferon alpha-2a biosimilar (Biolotus)

干扰素α-2a生物类似药 (Biolotus)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInterferon alpha-2a biosimilar (Biolotus)

Drug Alias Name干扰素α-2a生物仿制药 (Biolotus)Interferon α-2a biosimilar - BiolotusInterferon alfa-2a biosimilar - BiolotusINTEFEN-IFN

ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar

Mechanisms of ActionImmunomodulatorsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists

TargetsInterferon alpha/beta receptor

Therapy Area/IndicationsHematologic NeoplasmsLymphomaHepatitis C +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesBiolotus

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesN/A

Active IndicationsHematologic NeoplasmsLymphomaHepatitis C +[5]

Inactive IndicationsN/A

ATC CodeL03AB04